# Study of Radiolabeled ALXN2050 in Healthy Adult Males

> **NCT04609670** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]-ALXN2050

## Key facts

- **NCT ID:** NCT04609670
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-08-23
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609670, "Study of Radiolabeled ALXN2050 in Healthy Adult Males". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT04609670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*